arrow
C

Christine A. Iacobuzio-Donahue

Memorial Sloan Kettering Cancer Center
H指数:135
被引数:9.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

Pembrolizumab和olaparib治疗同源重组缺陷型转移性胰腺癌: 2期POLAR试验

2026-03-250
OAAI
Evidence that extra copies of chromosome 1q play a role in the early phases of pancreatic neoplasia

证据表明额外的1q染色体拷贝在胰腺新生物的早期阶段发挥作用

2026-02-200
OA
Genomic evolution of pancreatic cancer at single-cell resolution

单细胞分辨率的胰腺癌基因组进化

2026-01-220
OAAI
Safety and Feasibility of Intra-Arterial Treatment of Pancreatic Cancer Using an Emulsion of Ethiodized Oil plus Bumetanide in an Oncopig Model

使用乙碘油与布美他尼乳剂进行经动脉治疗胰腺癌的安全性与可行性:一项在肿瘤猪模型中的研究

2025-11-050
PRE
The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions

胰腺癌的非编码突变景观揭示了增强子区域中的复发体细胞突变

2025-10-010
PRE
SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence

SMAD4根据定居器官的不同,对胰腺肿瘤的转移性生长产生相反的影响。

2025-09-250
OAAI
Author Correction: Clonal evolution during metastatic spread in high-risk neuroblastoma

作者更正:高危神经母细胞瘤转移扩散过程中的克隆进化

2025-08-050
PRE
Cancer cells restrict immunogenicity of retrotransposon expression via distinct mechanisms

癌细胞通过不同机制限制反转录转座子表达的可免疫原性

IMMUNITY
IF26.3
2024-12-012
OAAI
Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum

II期临床试验,评估Pembrolizumab和OLApaRib(POLAR)用于具有同源重组缺陷(HRD)、非核心同源重组缺陷(ncHRD)以及对铂类药物有例外反应的转移性胰腺癌(mPC)患者的维持治疗。

2024-09-010
PRE
Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma
2024-07-061
OAAI
Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer
2024-06-284
OA
A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier
2024-06-121
PRE